Clinical Trial Update: A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating afatinib for persistent or recurrent HER2-positive uterine serous carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Serous Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Yale University | Conditions: HER2/Neu+ Uterine Serous Carcinoma | Phase 2 | Status: RECRUITING